Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies
Abstract
Article abstract The outcome of 34 women with anti-Yo–associated paraneoplastic cerebellar degeneration was reviewed. Three patients had not developed cancer after more than 4 years of follow-up. The only independent predictor for survival was the type of associated tumor (risk ratio, 1.79; 95% CI, 1.02 to 3.12). Median survival was 100 months for patients with breast cancer and 22 for those with gynecologic cancer. Although paraneoplastic cerebellar degeneration leads to the diagnosis of cancer in 63% of the patients, cancer progression was the cause of death in 52%.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Hammack JE, Kimmel DW, O’Neill BP, Lennon VA. Paraneoplastic cerebellar degeneration: a clinical comparison of patients with and without purkinje cell cytoplasmic antibodies. Mayo Clin Proc . 1990; 65: 1423–1431.
2.
Waterhouse DM, Natale RB, Cody RL. Breast cancer and paraneoplastic cerebellar degeneration. Cancer . 1991; 68: 1835–1841.
3.
Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration: I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology . 1992; 42: 1931–1937.
4.
Furneaux HM, Rosenblum MK, Dalmau J, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med . 1990; 322: 1844–1851.
5.
Keime-Guibert F, Graus F, Broët P, et al. Clinical outcome of patients with anti-Hu–associated encephalomyelitis after treatment of the tumor. Neurology . 1999; 53: 1719–1723.
6.
Hetzel DJ, Stanhope CR, O’Neill BP, Lennon VA. Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume. Mayo Clin Proc . 1990; 65: 1558–1563.
7.
McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med . 1996; 334: 1–6.
8.
Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and anti-Hu paraneoplastic syndrome: radiographic and CT findings. AJR Am J Radiol . 1998; 170: 1513–1517.
9.
Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol . 2000; 47: 9–17.
10.
Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol . 1997; 99: 9–22.
Information & Authors
Information
Published In
Copyright
© 2000.
Publication History
Received: January 25, 2000
Accepted: May 9, 2000
Published online: September 12, 2000
Published in print: September 12, 2000
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Paraneoplastic Cerebellar Degeneration Associated with Breast Cancer: A Case Report and a Narrative Review, Brain Sciences, 14, 2, (176), (2024).https://doi.org/10.3390/brainsci14020176
- Mechanisms of immune tolerance breakdown in paraneoplastic neurological syndromes, Revue Neurologique, (2024).https://doi.org/10.1016/j.neurol.2024.08.002
- Gynecologic clear cell carcinoma and paraneoplastic cerebellar Degeneration: A literature review and case study, Gynecologic Oncology Reports, 52, (101365), (2024).https://doi.org/10.1016/j.gore.2024.101365
- Paraneoplastic cerebellar and brainstem disorders, Paraneoplastic Neurologic Disorders, (173-191), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00030-X
- Overview of treatment strategies in paraneoplastic neurological syndromes, Paraneoplastic Neurologic Disorders, (97-112), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00015-3
- Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies, Paraneoplastic Neurologic Disorders, (409-417), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00014-1
- Changing landscape in the field of paraneoplastic neurology: Personal perspectives over a 35-year career, Paraneoplastic Neurologic Disorders, (11-32), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00013-X
- Epidemiology of paraneoplastic neurologic syndromes, Paraneoplastic Neurologic Disorders, (57-77), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00011-6
- Evolution of methods to detect paraneoplastic antibodies, Paraneoplastic Neurologic Disorders, (113-130), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00010-4
- Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors, Current Treatment Options in Oncology, 25, 1, (42-65), (2024).https://doi.org/10.1007/s11864-023-01157-1
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.